Drug Trial Radar · NCT00152204
The Community Effectiveness of IPTi in Southern Tanzania
Last checked: Nov 20, 2026Latest source record: May 22, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
13,000
Planned (sponsor's estimate)
Start
Mar 2005
Primary completion
Dec 2007
Study completion Dec 2008
Sponsor
- Lead sponsor
- Swiss Tropical & Public Health InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Ifakara Health Research and Development Centre; Ministry of Health, Tanzania; Hospital Clinic of Barcelona; London School of Hygiene and Tropical Medicine
- First posted
- Sep 9, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The safety and efficacy of Intermittent Preventive Treatment for malaria and anaemia control in Infants (IPTi) have already been documented in Southern Tanzania, affording an opportunity to gain operational experience in developing a strategy for the longer-term implementation of IPTi. Working in conjunction with national and district-based health authorities, a strategy will be developed to make IPTi available through routine health services and an effectiveness evaluation conducted. This will be based on the comparison of process and outcome indicators in areas with and without IPTi. Information on safety will be consolidated and the effect of IPTi on the rate of development of drug resistance explored. The acceptability and costs of implementing IPTi will be monitored and combined with assessments of effectiveness (in terms of morbidity and mortality) to assess the cost-effectiveness of IPTi.
Conditions
- Malaria, Falciparum
- Anemia
Interventions
Sulfadoxine-pyrimethamine used for IPTiDrug
Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
IPTiDrug
Doses of IPTi with SP delivered alongside doses 2 \& 3 of DTP/HB vaccination and alongside measles vaccination
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mortality rate in children aged 2-11 months (estimated by birth history questioning)Time frame: Up to 12 months of age
- Incidence of severe adverse drug reactions following IPTi (as detected by spontaneous, passive reporting system)Time frame: All age groups, particular attention in under 2 year olds
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ifakara Health Research & Development Centre
Dar es Salaam, Tanzania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.